CLINICAL TRIALS PROFILE FOR VABICASERIN

Clinical Trials for Vabicaserin

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00541996 ↗	Study Comparing Bioavailability of Oral Formulations of Vabicaserin	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.
NCT00563706 ↗	Study Evaluating Vabicaserin in Subjects With Schizophrenia	Completed	Pfizer	Phase 2	The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
NCT00768612 ↗	Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia	Withdrawn	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 2	This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia. The study will also assess the efficacy of vabicaserin and compare it to risperidone.

Clinical Trial Conditions for Vabicaserin

Condition Name

Condition Name for
Intervention	Trials
Schizophrenia	3
Healthy Subjects	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Schizophrenia	3

Clinical Trial Locations for Vabicaserin

Trials by Country

Trials by Country for
Location	Trials
United States	17
Canada	1

Trials by US State

Trials by US State for
Location	Trials
Pennsylvania	2
Massachusetts	1
Virginia	1
Texas	1
Oklahoma	1

Clinical Trial Progress for Vabicaserin

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	2
Phase 1	2

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	3
Withdrawn	1

Clinical Trial Sponsors for Vabicaserin

Sponsor Name

Sponsor Name for
Sponsor	Trials
Wyeth is now a wholly owned subsidiary of Pfizer	3
Pfizer	1

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	4